ESR2 and breast cancer: This discrepancy might be explained by the results of a recent study by Razandi et al[33]; tamoxifen targeted ERβ to induce apoptosis via increasing reactive oxygen species (ROS) in breast-cancer cell lines sensitive to tamoxifen therapy, but it functioned as an agonist to ERβ in resistant cell lines augmenting cell proliferation.